Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Quantitative analysis of local and regional myocardial perfusion between Lexiscan(TM) and dipyridamole rest/stress Rb82 PET
研究概览
简要总结
Lexiscan(TM) has ideal properties for Rb-82 PET imaging and the stress response it invokes may offer multiple advantages for the diagnosis of coronary disease and functional abnormalities. The goal of this investigation is to establish quantitative equivalence of Lexiscan(TM) rest/stress Rb-82 PET images to dipyridamole rest/stress images.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •No intervention or change in management between dipyridamole and Lexiscan(TM) PET
排除标准
- •An intervention or change in management between dipyridamole and Lexiscan(TM) PET
研究组 & 干预措施
LL for CAD
Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
干预措施: Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT (Drug)
LL for CAD
Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
干预措施: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET (Drug)
CAD
Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
干预措施: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET (Drug)
结局指标
主要结局
Quantitative analysis of local and regional myocardial perfusion between Lexiscan(TM) and dipyridamole rest/stress Rb82 PET
时间窗: 12 months
次要结局
未报告次要终点
研究者
Timothy M. Bateman, MD
Principal Investigator
Cardiovascular Imaging Technologies